![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 304, Issue 3, 1209-1216, March 2003
Department of Pharmacology and Experimental Therapeutics and Center
for Serotonin Disorders Research, Loyola University Chicago, Stritch
School of Medicine, Maywood, Illinois
The 5-hydroxytryptamine2A and 2C
(5-HT2A and 5-HT2C) receptors are so closely
related that selective agonists have not been developed until recently
with the advent of
(S)-2-(chloro-5-fluoro-indol-l-yl)-1-methylethylamine fumarate (Ro 60-0175), a putatively selective 5-HT2C
receptor agonist. In the present study, Ro 60-0175 was used to analyze the importance of 5-HT2C receptors in hormone secretion.
Injection of Ro 60-0175 (5 mg/kg s.c.) produced a maximum increase in
plasma levels of adrenocorticotrophic hormone, oxytocin, and
prolactin at 15 min postinjection and a maximum increase in plasma
corticosterone levels at 60 min postinjection. Ro 60-0175-mediated
increases in plasma hormone levels were dose-dependent (corticosterone
ED50 = 2.43 mg/kg; oxytocin ED50 = 4.19 mg/kg; and prolactin ED50 = 4.03 mg/kg). To
assess the role of 5-HT2C and 5-HT2A receptors in mediating the hormone responses to Ro 60-0175, rats were pretreated with the 5-HT2C antagonist
6-chloro-5-methyl-1-[2-(2-methylpyridyl-3-oxy)-pyrid-5-yl carbonyl]
indoline (SB 242084) or 5-HT2A antagonists
(±)-2,3-dimethoxyphenyl-1-[2-4-(piperidine)-methanol] (MDL 100,907)
before injection of Ro 60-0175 (5 mg/kg s.c.). Neither SB 242084 (0.1, 0.5, 1, and 5 mg/kg i.p.) nor MDL 100,907 (1, 5, and 10 µg/kg s.c.)
significantly inhibited the Ro 60-0175-induced increases in plasma
hormone levels. The data suggest that Ro 60-0175 increases hormone
secretion by mechanisms independent of the activation of
5-HT2C and/or 5-HT2A receptors and suggest that
Ro 60-0175 is not a highly selective 5-HT2C receptor agonist.